Holen Sie sich die Stockscreener-App
31.78
2.49%
-0.8062
Schlusskurs vom Vortag:
$32.59
Offen:
$32.2
24-Stunden-Volumen:
274.43K
Relative Volume:
0.34
Marktkapitalisierung:
$2.05B
Einnahmen:
$32.08M
Nettoeinkommen (Verlust:
$-169.77M
KGV:
-11.18
EPS:
-2.8418
Netto-Cashflow:
$-147.70M
1W Leistung:
-1.58%
1M Leistung:
+8.13%
6M Leistung:
-12.72%
1J Leistung:
+60.75%
1-Tages-Spanne:
$31.71
$32.55
1-Wochen-Bereich:
$31.16
$33.94
52-Wochen-Spanne:
$18.80
$40.22
Stoke Therapeutics Inc Stock (STOK) Company Profile
Firmenname
Stoke Therapeutics Inc
Sektor
Branche
Telefon
781-430-8200
Adresse
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
31.78 | 2.03B | 32.08M | -169.77M | -147.70M | -2.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
543.56 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
792.69 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,031.33 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.79 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
207.51 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-02-05 | Eingeleitet | Guggenheim | Buy |
| 2026-01-05 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2025-07-18 | Eingeleitet | Jefferies | Buy |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-03-26 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-07-25 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Fortgesetzt | Canaccord Genuity | Buy |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-10-24 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Eingeleitet | Jefferies | Buy |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-11-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Eingeleitet | UBS | Neutral |
| 2021-05-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-12-11 | Bestätigt | Needham | Buy |
| 2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-29 | Eingeleitet | Needham | Buy |
| 2019-12-18 | Eingeleitet | Wedbush | Outperform |
| 2019-11-12 | Eingeleitet | BTIG Research | Buy |
| 2019-10-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Credit Suisse | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
STOK Reinstated by JP Morgan -- Price Target Set at $40 - GuruFocus
Stoke Therapeutics (NASDAQ:STOK) Earns Overweight Rating from Analysts at JPMorgan Chase & Co. - MarketBeat
Goldminenunternehmen, Ross Stores, Stoke Therapeutics - TradingView
STOK Looks 225.6% Overvalued on GF Value™ - GuruFocus
Why is Stoke Therapeutics stock gaining today? By Investing.com - Investing.com Canada
Stoke Therapeutics shares rise as JPMorgan starts coverage with Overweight rating - Yahoo Finance
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 7.9%What's Next? - MarketBeat
Bank of America Corp DE Buys 336,931 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke (STOK) Results Breakdown: The Available Earnings Metric Delivers a Miss in the Reported Period; Share Response: The Stock Records a 2.77% Increase in the Latest ReadingPerformance Review - Vinanet
Is Strong EMPEROR Trial Enrollment and Retention Altering The Investment Case For Stoke Therapeutics (STOK)? - simplywall.st
Stoke (STOK) Quarterly Figures: EPS Falls Short of Its Estimate for the Current Session; Share Move: The Stock Gains 2.64% in the Current UpdateLow Estimate Range - Vinanet
Stoke Therapeutics general counsel Allan sells $91,639 in stock By Investing.com - Investing.com Australia
Stoke therapeutics CMO Barry Ticho sells $152k in stock By Investing.com - Investing.com Australia
Stoke Therapeutics’ director Kaye sells $402,528 in shares By Investing.com - Investing.com Australia
Stoke Therapeutics general counsel Allan sells $91,639 in stock - Investing.com
Stoke Therapeutics’ director Kaye sells $402,528 in shares - Investing.com
Stoke therapeutics CMO Barry Ticho sells $152k in stock - Investing.com
Edward Md Kaye Sells 12,567 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Insider Sells 4,767 Shares of Stock - MarketBeat
Stoke Therapeutics (STOK) insider sale tied to tax withholding - Stock Titan
Stoke Therapeutics (NASDAQ: STOK) CMO gets 10,000 shares, sells some for taxes - Stock Titan
Stoke Therapeutics (STOK) director share sale tied to taxes - Stock Titan
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Stoke (STOK) Session-Level Review: Closes 0.70% Higher at $32.35 on the Day; Nearby Levels: Price Remains Between $30.73 Support and $33.97 Resistance on the DayEarnings Beat Stocks - Vinanet
Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts - TradingView
Stoke Therapeutics (STOK) gets 6.5% stake disclosure from Lynx1 Capital - Stock Titan
Trading Systems Reacting to (STOK) Volatility - Stock Traders Daily
Stoke Therapeutics (STOK) Slips 0.99% to $32.65 as Shares Consolidate Between Key Support and ResistanceWeak Sell Signals - Vinanet
Stoke Therapeutics (STOK): TD Bank, TD Securities disclose 4.9% equity stake - Stock Titan
Stoke Therapeutics at canaccord growth conference: trial momentum builds By Investing.com - Investing.com Canada
Stoke Therapeutics at canaccord growth conference: trial momentum builds - Investing.com
Stoke Therapeutics (STOK) Short Interest & Short Float | Updated Aug 2026 $STOK - MarketBeat
Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript - The Globe and Mail
Stoke Therapeutics, Inc. $STOK Shares Acquired by Assenagon Asset Management S.A. - MarketBeat
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - The National Law Review
Stoke Therapeutics, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:STOK) 2026-08-07 - Seeking Alpha
Stoke Therapeutics Inc (STOK) Stock News Today - TradingKey
Stoke Therapeutics, Inc. (STOK) Investor Outlook: A Promising 43.5% Upside In Biotech's Genetic Revolution - DirectorsTalk Interviews
What Is Stoke Therapeutics (STOK) Signaling With A 2 Million Share Shelf Filing? - Yahoo Finance
FMR LLC discloses 8.5% Stoke Therapeutics (STOK) ownership in Schedule 13G/A - Stock Titan
Analysts Have Made A Financial Statement On Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Second-Quarter Report - simplywall.st
Q3 EPS Estimates for Stoke Therapeutics Cut by HC Wainwright - MarketBeat
Stoke Therapeutics (STOK) CMO sells 7,176 shares under 10b5-1 plan - Stock Titan
A Quick Look at Today's Ratings for Stoke Therapeutics(STOK.US), With a Forecast Between $40 to $60 - Moomoo
Stoke: 'Buy' Zorevunersen NDA SCN1A DS And STK-002 Advancement (NASDAQ:STOK) - Seeking Alpha
Stoke Therapeutics CMO Barry Ticho disposes of USD 208,707 in common shares - Bitget
Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference - marketscreener.com
Dimensional Fund Advisors LP Buys 162,797 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
STOK Maintained by Canaccord Genuity -- Price Target Lowered to $58 - GuruFocus
These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results - webull.com
STOK Maintains Rating by Wedbush -- Price Target Raised to $40 - GuruFocus
Finanzdaten der Stoke Therapeutics Inc-Aktie (STOK)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):